Home / Business and Economy / Pharma IPO: Funds for Growth & Risks Ahead
Pharma IPO: Funds for Growth & Risks Ahead
1 May
Summary
- IPO involves 1.41 crore equity shares, including fresh issuance.
- Proceeds to fund working capital and general corporate needs.
- Company faces competitive market, client dependency, and equipment risks.
Hindustan Laboratories is preparing for an Initial Public Offering (IPO), which will consist of 1.41 crore equity shares. A portion of these shares will be a fresh issuance, while the remainder will be offered by the company's promoter.
The capital raised through the fresh equity issuance is designated for specific purposes. Approximately Rs 72.5 crore is earmarked for funding the company's working capital needs. The remaining funds will be allocated towards general corporate purposes, providing flexibility for future business operations.
Operating within the Indian pharmaceutical sector presents several inherent risks. The market is characterized by intense competition. Hindustan Laboratories' operations could be affected by equipment failures and a significant reliance on government tenders for business.
Further vulnerabilities include a high dependence on its top ten clients for revenue generation. The company must also navigate risks associated with failing to meet stringent quality requirements and managing related party transactions. Ensuring sufficient cash flow generation is another critical factor for the company's stability.
